Table 1 Basic characteristic data of total gastric cancer patients and gastric cancer patients after PSM.
| Â | Entire cohort | Cohort after PSM | ||||
|---|---|---|---|---|---|---|
CTA (n = 125) | Non-CTA (n = 89) | P | CTA (n = 75) | Non-CTA (n = 75) | P | |
Sex | ||||||
 Male | 97 (77.6%) | 72 (80.9%) | 0.559 | 57 (76.0%) | 60 (80.0%) | 0.554 |
 Female | 28 (22.4%) | 17 (19.1%) | 18 (24.0%) | 15 (20.0%) | ||
Age (years) | 59.34 ± 10.23 | 60.92 ± 9.34 | 0.374 | 60.43 ± 10.27 | 60.21 ± 9.56 | 0.712 |
BMI (kg/cm2) | 24.15 ± 3.28 | 24.41 ± 3.63 | 0.315 | 24.04 ± 3.30 | 24.25 ± 3.63 | 0.515 |
Surgical procedure | ||||||
 Proximal gastrectomy | 12 (9.6%) | 13 (14.6%) | 0.042 | 7 (9.3%) | 11 (14.7%) | 0.346 |
 Distal gastrectomy | 68 (54.4%) | 33 (37.1%) | 36 (48%) | 28 (37.3%) | ||
 Total gastrectomy | 45 (36.0%) | 43 (48.3%) | 32 (42.7%) | 36 (48.0%) | ||
Surgical approach | ||||||
 Laparoscopic assistance | 83 (66.4%) | 71 (79.8%) | 0.032 | 59 (78.7%) | 61 (81.3%) | 0.683 |
 Total laparoscopic | 42 (33.6%) | 18 (20.2%) | 16 (21.3%) | 14 (18.7%) | ||
Tumor stage | ||||||
 I | 52 (41.6%) | 34 (38.2%) | 0.670 | 33 (44.0%) | 26 (34.7%) | 0.247 |
 II | 35 (28.0%) | 30 (33.7%) | 17 (22.7%) | 26 (34.7%) | ||
 III | 38 (30.4%) | 25 (28.1%) | 25 (33.3%) | 23 (30.7%) | ||
Tumor differentiation | ||||||
Low | 70 (56.0%) | 42 (47.2%) | 0.561 | 39 (52.0%) | 36 (48.0%) | 0.547 |
 Low–middle | 23 (18.4%) | 18 (20.2%) | 13 (17.3%) | 16 (21.3%) | ||
 Middle | 17 (13.6%) | 19 (21.3%) | 11 (14.7%) | 16 (21.3%) | ||
 Middle–high | 9 (7.2%) | 5 (5.6%) | 7 (9.3%) | 3 (4.0%) | ||
 High | 6 (4.8%) | 5 (5.6%) | 5 (6.7%) | 4 (5.3%) | ||
Gastrointestinal reconstruction methods | ||||||
 Tubular gastric anastomosis | 5 (4.0%) | 5 (5.6%) | 0.025 | 1 (1.3%) | 5 (6.7%) | 0.775 |
 Billroth-II | 65 (52.0%) | 30 (33.7%) | 32 (42.7%) | 28 (37.3%) | ||
 Roux-en-y | 49 (39.2%) | 40 (44.9%) | 36 (48.0%) | 36 (48.0%) | ||
 Reverse puncture anastomosis | 5 (4.0%) | 8 (9.0%) | 5 (6.7%) | 6 (8.0%) | ||
 Overlap anastomosis | 1 (0.8%) | 3 (3.4%) | 1 (1.3%) | 0 (0%) | ||
 Billroth-I | 0 (0%) | 3 (3.4%) | 0 (0%) | 0 (0%) | ||
Charlson comorbidity index | ||||||
 2 | 26 (20.8%) | 6 (6.7%) | 0.030 | 9 (12.0%) | 5 (6.7%) | 0.633 |
 3 | 33 (26.4%) | 17 (19.1%) | 18 (24.0%) | 16 (21.3%) | ||
 4 | 37 (29.6%) | 36 (40.4%) | 27 (36.0%) | 31 (41.3%) | ||
 5 | 22 (17.6%) | 23 (25.8%) | 14 (18.7%) | 17 (22.7%) | ||
 6 | 3 (2.4%) | 5 (5.6%) | 3 (4.0%) | 5 (6.7%) | ||
 7 | 3 (2.4%) | 1 (0.8%) | 3 (4.0%) | 1 (1.3%) | ||
 8 | 0 (0%) | 1 (0.8%) | 0 (0%) | 0 (0%) | ||
 10 | 1 (0.8%) | 0 (0%) | 1 (1.3%) | 0 (0%) | ||
